| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NOVARTIS | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618174 | NOVARTIS | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Nov, 2021
(2 years ago) | |
| US8183295 | NOVARTIS | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
May, 2023
(11 months ago) | |
Amturnide is owned by Novartis.
Amturnide contains Aliskiren Hemifumarate; Amlodipine Besylate; Hydrochlorothiazide.
Amturnide has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Amturnide are:
- US8618174
- US8183295
- US5559111
Amturnide was authorised for market use on 21 December, 2010.
Amturnide is available in tablet;oral dosage forms.
Amturnide can be used as treatment of hypertension.
Drug patent challenges can be filed against Amturnide from 06 March, 2011.
The generics of Amturnide are possible to be released after 16 May, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Dec 21, 2013 |
NCE-1 date: 06 March, 2011
Market Authorisation Date: 21 December, 2010
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
More Information on Dosage
AMTURNIDE family patents
